Reeler: new tales on an old mutant mouse
β Scribed by Gabriella D'Arcangelo; Tom Curran
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 137 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0265-9247
No coin nor oath required. For personal study only.
β¦ Synopsis
Neurological mouse mutants provide an opportunity to dissect the complex mechanisms that underlie vertebrate brain development. Advances in genetic technologies have permitted the identification of genes disrupted in many mutants, allowing a molecular interpretation of the phenotypes. For several decades, the spontaneous mutant mouse reeler has been used as a model for the analysis of the development of laminated brain structures. In this ataxic mutant, the migration of many neurons is aberrant, resulting in disrupted cellular organization. Recently, reelin, the gene disrupted in the reeler mouse, has been identified. reelin encodes a novel extracellular molecule that controls neural cell positioning through mechanisms that are not yet completely understood. Analysis of the expression pattern and the properties of the reelin gene product (Reelin) suggests models for its function during brain development. Furthermore, the recent identification of genes that may function in the Reelin signaling pathway advances our knowledge of the molecular basis of neuronal migration.
π SIMILAR VOLUMES
This article discusses recent advances in basic research that alter the view of the pathogenesis of radiation myelopathy and summarizes the available data from developmental neurobiology and preclinical studies on demyelinating diseases. These studies have produced interesting insights into oligoden
Clinicians have been trained to use statistics to identify differences and to reject apparent differences that may have occurred by chance. The objective of studies such as that by Ramond et al. is not to prove that the groups of patients are different at randomization but that they are similar. Sim
HEPATOLOGY Elsewhere 973 6 mo of the study. Furthermore, six study patients treated with ursodeoxycholic acid failed therapy, indicating that not all PBC patients treated with ursodeoxycholic acid therapy respond. Of equal importance, no patient in either group was noted to have a complete clinical,